0000899243-23-015406.txt : 20230612 0000899243-23-015406.hdr.sgml : 20230612 20230612193455 ACCESSION NUMBER: 0000899243-23-015406 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230608 FILED AS OF DATE: 20230612 DATE AS OF CHANGE: 20230612 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FONTEYNE PAUL R. CENTRAL INDEX KEY: 0001727550 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 231009869 MAIL ADDRESS: STREET 1: C/O RESTORBIO, INC. STREET 2: 501 BOYLSTON STREET SUITE 6102 CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-08 0 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001727550 FONTEYNE PAUL R. C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET CAMBRIDGE MA 02141 1 0 0 0 0 Stock Option (right to buy) 26.25 2023-06-08 4 A 0 16985 0.00 A 2033-06-08 Common Stock 16985 16985 D The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Exhibit List: Exhibit 24. This Power of Attorney was inadvertently omitted from the Form 3 filed on January 6, 2022. /s/ Joshua B. Cohen, as Attorney in Fact 2023-06-12 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                POWER OF ATTORNEY

    Know all by these presents, that the undersigned hereby constitutes and
appoints each of Joshua Cohen, Justin Klee and James Frates, signing
singly, the undersigned's true and lawful attorney-in-fact to:

(1)   execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of Amylyx Pharmaceuticals, Inc. (the
"Company"), (i) Form ID, including any attached documents, to effect the
assignment of codes to the undersigned to be used in the transmission of
information to the United States Securities and Exchange Commission using the
EDGAR System, and (ii) Forms 3, 4 and 5 and amendments thereto in accordance
with Section 16(a) of the Securities Exchange Act of 1934, as amended, and
the rules thereunder;

(2)   do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3,
4 or 5 and amendments thereto and timely file such form with the United
States Securities and Exchange Commission and any stock exchange or similar
authority; and

(3)   take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it
being understood that the documents executed by such attorney-in-fact on
behalf of the undersigned pursuant to this Power of Attorney shall be in such
form and shall contain such terms and conditions as such attorney-in-fact may
approve in such attorney-in-fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the
rights and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of
the undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify
the attorney-in-fact and the Company from and against any demand, damage,
loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorney-in-fact.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact. This Power of Attorney may be
filed with the United States Securities and Exchange Commission as a
confirming statement of the authority granted herein. This Power of Attorney
supersedes any prior power of attorney in connection with the undersigned's
capacity as an officer and/or director of the Company. This Power of Attorney
shall expire as to any individual attorney-in-fact if such attorney-in-fact
ceases to be an executive officer of, or legal counsel to, the Company.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of December 29, 2021.


/s/ Paul Fonteyne
Name:  Paul Fonteyne